- Home
- TC vs AYTU Comparison
TC vs AYTU Comparison
Compare TC & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TC
- AYTU
- Stock Information
- Founded
- TC 2010
- AYTU N/A
- Country
- TC China
- AYTU United States
- Employees
- TC N/A
- AYTU N/A
- Industry
- TC Business Services
- AYTU Biotechnology: Pharmaceutical Preparations
- Sector
- TC Consumer Discretionary
- AYTU Health Care
- Exchange
- TC Nasdaq
- AYTU Nasdaq
- Market Cap
- TC 25.0M
- AYTU 23.0M
- IPO Year
- TC 2018
- AYTU N/A
- Fundamental
- Price
- TC $15.38
- AYTU $2.19
- Analyst Decision
- TC
- AYTU Strong Buy
- Analyst Count
- TC 0
- AYTU 3
- Target Price
- TC N/A
- AYTU $9.17
- AVG Volume (30 Days)
- TC 15.9K
- AYTU 182.8K
- Earning Date
- TC 12-16-2025
- AYTU 11-13-2025
- Dividend Yield
- TC N/A
- AYTU N/A
- EPS Growth
- TC N/A
- AYTU N/A
- EPS
- TC N/A
- AYTU N/A
- Revenue
- TC $5,115,721.00
- AYTU $66,382,000.00
- Revenue This Year
- TC N/A
- AYTU N/A
- Revenue Next Year
- TC N/A
- AYTU $29.12
- P/E Ratio
- TC N/A
- AYTU N/A
- Revenue Growth
- TC N/A
- AYTU 1.84
- 52 Week Low
- TC $9.20
- AYTU $0.95
- 52 Week High
- TC $39.00
- AYTU $2.82
- Technical
- Relative Strength Index (RSI)
- TC 56.46
- AYTU 46.28
- Support Level
- TC $14.50
- AYTU $2.23
- Resistance Level
- TC $16.00
- AYTU $2.31
- Average True Range (ATR)
- TC 1.49
- AYTU 0.12
- MACD
- TC -0.32
- AYTU -0.02
- Stochastic Oscillator
- TC 31.10
- AYTU 14.04
About TC TuanChe Limited
Token Cat Ltd is an omnichannel automotive marketplace in China. The company operates in one segment, providing auto shows, special promotion event services, virtual dealerships, online marketing services, and more. It organizes auto shows to facilitate transactions between consumers and auto dealers, which include auto dealers, automakers, and automotive service providers. It offers services through its online platform and offline events.
About AYTU Aytu BioPharma Inc.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.